Pre-surgery treatment with pucotenlimab and becotatug vedotin for penile cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two drugs given before surgery for penile cancer that has spread to nearby tissues or lymph nodes. The goal is to see if this combination can shrink tumors and improve outcomes. The drugs work by helping the immune system attack cancer cells and delivering chemotherapy directly to them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 to 75.
- You have penile cancer that is squamous cell type and has spread to nearby tissues or lymph nodes but not to distant organs.
- You have not had prior treatment for this cancer, or your last treatment was at least 12 months ago.
- You have at least one tumor that can be measured on scans.
- You are in good general health (able to care for yourself) and have adequate organ function.
- You have not had prior therapy with PD-1/PD-L1 inhibitors or EGFR-targeting drugs like becatotug vedotin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (paclitaxel, ifosfamide, cisplatin) and an immunotherapy drug (triplizumab) given before surgery for locally advanced penile cancer. The goal is to shrink the tumor and improve outcomes.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
Hear when a new Penile Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.